An Overview of the GeparSepto Trial in Luminal, Triple-Negative, and HER2+ Breast Cancer

January 5, 2017
Sibylle Loibl, MD, PhD

Sibylle Loibl, MD, PhD, co-chair of the German Breast Group and associate professor at the University of Frankfurt, discusses the most recent subanalysis of the GeparSepto trial in luminal, triple-negative, and HER2+ breast cancer.